Cargando…
Editorial Commentary: Linezolid vs Daptomycin for Vancomycin-Resistant Enterococci: The Evidence Gap Between Trials and Clinical Experience
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Oxford University Press
2015
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4551011/ https://www.ncbi.nlm.nih.gov/pubmed/26063714 http://dx.doi.org/10.1093/cid/civ449 |
| _version_ | 1782387528300494848 |
|---|---|
| author | McKinnell, James A. Arias, Cesar A. |
| author_facet | McKinnell, James A. Arias, Cesar A. |
| author_sort | McKinnell, James A. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-4551011 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2015 |
| publisher | Oxford University Press |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-45510112015-08-28 Editorial Commentary: Linezolid vs Daptomycin for Vancomycin-Resistant Enterococci: The Evidence Gap Between Trials and Clinical Experience McKinnell, James A. Arias, Cesar A. Clin Infect Dis Articles and Commentaries Oxford University Press 2015-09-15 2015-06-10 /pmc/articles/PMC4551011/ /pubmed/26063714 http://dx.doi.org/10.1093/cid/civ449 Text en © The Author 2015. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com. |
| spellingShingle | Articles and Commentaries McKinnell, James A. Arias, Cesar A. Editorial Commentary: Linezolid vs Daptomycin for Vancomycin-Resistant Enterococci: The Evidence Gap Between Trials and Clinical Experience |
| title | Editorial Commentary: Linezolid vs Daptomycin for Vancomycin-Resistant Enterococci: The Evidence Gap Between Trials and Clinical Experience |
| title_full | Editorial Commentary: Linezolid vs Daptomycin for Vancomycin-Resistant Enterococci: The Evidence Gap Between Trials and Clinical Experience |
| title_fullStr | Editorial Commentary: Linezolid vs Daptomycin for Vancomycin-Resistant Enterococci: The Evidence Gap Between Trials and Clinical Experience |
| title_full_unstemmed | Editorial Commentary: Linezolid vs Daptomycin for Vancomycin-Resistant Enterococci: The Evidence Gap Between Trials and Clinical Experience |
| title_short | Editorial Commentary: Linezolid vs Daptomycin for Vancomycin-Resistant Enterococci: The Evidence Gap Between Trials and Clinical Experience |
| title_sort | editorial commentary: linezolid vs daptomycin for vancomycin-resistant enterococci: the evidence gap between trials and clinical experience |
| topic | Articles and Commentaries |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4551011/ https://www.ncbi.nlm.nih.gov/pubmed/26063714 http://dx.doi.org/10.1093/cid/civ449 |
| work_keys_str_mv | AT mckinnelljamesa editorialcommentarylinezolidvsdaptomycinforvancomycinresistantenterococcitheevidencegapbetweentrialsandclinicalexperience AT ariascesara editorialcommentarylinezolidvsdaptomycinforvancomycinresistantenterococcitheevidencegapbetweentrialsandclinicalexperience |